Independent
Tenure on this board
3.0 yrs
Meeting calendar
ZYME · Annual meeting · Tuesday, December 30, 2025
Zymeworks Inc
3 nominees · 3 ballot items.
Election of three Class I directors, advisory say-on-pay for named executive officers, and ratification of KPMG as auditors for 2025.
Market cap
$1.8B
1Y TSR
+83.6%
Board grade
B-
Record date
Nov 3, 2025
Filing
DEF 14A
Meeting concluded · Dec 30, 2025
Follow how the vote landed and what changed on Zymeworks Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElection of three Class I directors to hold office until the 2028 annual meeting of stockholders or until their successors are duly elected and qualified, subject to earlier resignation or removal.
- 2
Advisory Vote on the Compensation of Our Named Executive Officers
ManagementBoard: FORNon-binding advisory vote on the compensation of our named executive officers as disclosed in this proxy statement.
- 3
Ratification of the Appointment of Auditors
ManagementBoard: FORRatify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
2.4 yrs
Also a director at
Puma Biotechnology Inc (PBYI)Summit Therapeutics Inc (SMMT)
Independent
Tenure on this board
0.9 yrs
Also a director at
Cytokinetics Inc (CYTK)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 31.5% | 22,970,388 | $575M |
| 2 | Rubric Capital Management LP | 9.6% | 7,000,000 | $175M |
| 3 | BVF INC/IL | 5.1% | 3,734,142 | $94M |
| 4 | PERCEPTIVE ADVISORS LLC | 4.8% | 3,510,078 | $88M |
| 5 | BlackRock, Inc. | 3.3% | 2,412,123 | $60M |
| 6 | MORGAN STANLEY | 3.1% | 2,287,435 | $57M |
| 7 | BNP Paribas Asset Management Holding S.A. | 2.4% | 1,749,171 | $44M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 2.3% | 1,705,580 | $43M |
| 9 | Nextech Invest, Ltd. | 1.5% | 1,113,946 | $28M |
| 10 | DIMENSIONAL FUND ADVISORS LP | 1.5% | 1,067,139 | $27M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Zymeworks Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$712M
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Reference
Frequently asked questions
- When is the Zymeworks Inc 2025 annual meeting?
- Zymeworks Inc (ZYME) holds its 2025 annual shareholder meeting on Tuesday, December 30, 2025.
- What is the record date for the Zymeworks Inc 2025 meeting?
- The record date for the Zymeworks Inc 2025 meeting is Monday, November 3, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Zymeworks Inc's 2025 meeting?
- The board is presenting 3 director nominees at the Zymeworks Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Zymeworks Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Zymeworks Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.